Brokerages Set Biohaven Ltd. (NYSE:BHVN) Price Target at $61.92

Biohaven Ltd. (NYSE:BHVN - Get Free Report) has been given a consensus rating of "Buy" by the fourteen research firms that are currently covering the company, Marketbeat reports. Thirteen research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $61.92.

A number of equities research analysts recently commented on the stock. Piper Sandler raised their price objective on shares of Biohaven from $66.00 to $76.00 and gave the stock an "overweight" rating in a report on Monday, September 23rd. HC Wainwright reiterated a "buy" rating and issued a $59.00 price target on shares of Biohaven in a research note on Tuesday, September 24th. Jefferies Financial Group started coverage on shares of Biohaven in a research note on Monday, September 16th. They issued a "buy" rating and a $57.00 price target on the stock. UBS Group lowered their price target on shares of Biohaven from $55.00 to $54.00 and set a "buy" rating on the stock in a research note on Tuesday, August 13th. Finally, Morgan Stanley started coverage on shares of Biohaven in a research note on Wednesday, July 24th. They issued an "overweight" rating and a $58.00 price target on the stock.

Insider Transactions at Biohaven

In other news, Director Gregory Bailey bought 5,000 shares of the company's stock in a transaction dated Tuesday, September 24th. The stock was bought at an average price of $44.19 per share, with a total value of $220,950.00. Following the completion of the acquisition, the director now owns 1,620,071 shares of the company's stock, valued at $71,590,937.49. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. In related news, Director John W. Childs purchased 21,052 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The stock was acquired at an average cost of $47.50 per share, for a total transaction of $999,970.00. Following the completion of the purchase, the director now owns 21,052 shares in the company, valued at approximately $999,970. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gregory Bailey purchased 5,000 shares of the business's stock in a transaction that occurred on Tuesday, September 24th. The stock was bought at an average price of $44.19 per share, with a total value of $220,950.00. Following the completion of the purchase, the director now owns 1,620,071 shares of the company's stock, valued at $71,590,937.49. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 16.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Biohaven

Several institutional investors have recently made changes to their positions in BHVN. nVerses Capital LLC acquired a new position in Biohaven during the third quarter valued at approximately $50,000. Redwood Wealth Management Group LLC acquired a new position in Biohaven during the second quarter valued at approximately $61,000. Values First Advisors Inc. acquired a new position in Biohaven during the third quarter valued at approximately $78,000. US Bancorp DE raised its position in Biohaven by 57.1% during the third quarter. US Bancorp DE now owns 2,173 shares of the company's stock valued at $109,000 after purchasing an additional 790 shares in the last quarter. Finally, KBC Group NV raised its position in Biohaven by 24.5% during the third quarter. KBC Group NV now owns 2,250 shares of the company's stock valued at $112,000 after purchasing an additional 443 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors.

Biohaven Stock Down 0.0 %

Shares of NYSE:BHVN traded down $0.01 during midday trading on Thursday, reaching $53.73. 156,815 shares of the company were exchanged, compared to its average volume of 1,142,847. Biohaven has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The stock has a fifty day simple moving average of $46.50 and a two-hundred day simple moving average of $40.37. The firm has a market cap of $5.08 billion, a PE ratio of -5.87 and a beta of 1.31.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($3.64) EPS for the quarter, missing analysts' consensus estimates of ($1.72) by ($1.92). As a group, analysts forecast that Biohaven will post -8.81 earnings per share for the current year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.